[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
|
[2] |
Oh DY, Bang YJ. HER2-targeted therapies-a role beyond breast cancer[J]. Nat Rev Clin Oncol,2020,17(1):33-48.
|
[3] |
Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now[J]. NPJ Breast Cancer,2021,7(1):56.
|
[4] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol,2014,32(33):3744-3752.
|
[5] |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med,2019,380(7):617-628.
|
[6] |
Sibylle L, Max M, Michael U, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis [EB/OL]. [2024-03-01].
URL
|
[7] |
Hurvitz SA, Bachelot T, Bianchini G, et al. ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer[J]. Future Oncol,2022,18(32):3563-3572.
|
[8] |
O’Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+tucatinib/placebo in patients with residual HER2-positive invasive breast cancer[J]. Future Oncol,2021,17(34):4665-4676.
|
[9] |
Geyer CE Jr, Untch M, Prat A, et al. Abstract OT-03-01: trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05) [J]. Cancer Res,2021,81(Suppl 4):OT-03-01
|
[10] |
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol,2006,24(18):2786-2792.
|
[11] |
Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol,2020,21(4):519-530.
|
[12] |
Ma F, Yan M, Li W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial[J]. BMJ,2023,383:e076065.
|
[13] |
Qingyuan Z, Jingxuan W, Quchang O, et al. Two and a half years follow-up data of HER2-targeted bispecific antibody KN026 combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer[EB/OL]. [2024-03-01].
URL
|
[14] |
Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet,2023,401(10371):105-117.
|
[15] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) breast cancer version 2.2024[EB/OL]. [2024-03-01].
URL
|
[16] |
中国抗癌协会乳腺癌专业委员会,中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志,2023, 33(12): 1092-1187.
|
[17] |
Sara H, Sherene L, Joyce OS, et al. HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated Her2-positive metastatic breast cancer[EB/OL]. [2024-03-01].
URL
|
[18] |
Aftimos PG, Turner N, O’Shaughnessy J, et al. 386MO Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial[EB/OL]. [2024-03-01].
URL
|
[19] |
Adrienne W, Ruichao S, Meredith R, et al. AVIATOR/TBCRC045: a randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)[EB/OL]. [2024-03-01].
URL
|
[20] |
Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol,2020,21(10):1283-1295.
|
[21] |
Herui Y, Min YZ, Zhongsheng T, et al. Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study [J]. Cancer Res,2023,83(8 Suppl):Abstract nr CT175.
|
[22] |
Qiao L, Ying C, Zhongsheng T, et al. FS-1502 in HER2-positive advanced breast cancer: results from an open-label, phase 1 study[J]. J Clin Oncol,2023, 41(16 Suppl):3044.
|
[23] |
Fei M, Nong X, Huoling T, et al. A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors[J]. Munster J Clin Oncol, 2023, 41(16 Suppl):3029.
|
[24] |
Lin NU, Amiri-Kordestani L, Palmieri D, et al. CNS metastases in breast cancer: old challenge, new frontiers[J]. Clin Cancer Res,2013,19(23):6404-6418.
|
[25] |
Niu L, Lv H, Zhang M, et al. Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases[J]. Ann Transl Med,2021,9(16):1331.
|
[26] |
Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update[J]. J Clin Oncol,2018,36(27):2804-2807.
|
[27] |
Mair MJ, Bartsch R, Le Rhun E, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours[J]. Nat Rev Clin Oncol,2023,20(6):372-389.
|
[28] |
Hurvitz SA, Modi S, Li W, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03[EB/OL]. [2024-03-01].
URL
|
[29] |
AstraZeneca.Trastuzumab deruxtecan (T-DXd) alone or in sequence with THP, versus standard treatment (ddAC-THP), in HER2-positive early breast cancer [EB/OL]. [2024-03-01].
URL
|
[30] |
Javier C, José MP, Manuel RB, et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) [J]. J Clin Oncol,2023,41(17 Suppl):LBA506.
|
[31] |
Pier FC, Giancarlo B, Federico P, et al. Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial [J]. J Clin Oncol,2023,41(17 Suppl):LBA637.
|
[32] |
AstraZeneca. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09) [EB/OL]. [2024-03-01].
URL
|
[33] |
Shanghai JMT-Bio Inc. Efficacy and safety of KN026 in combination with HB1801 in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer [EB/OL]. [2024-03-01].
URL
|
[34] |
Lin NU, Ciruelos E, Jerusalem G, et al. Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast12[EB/OL]. [2024-03-01].
URL
|